同核蛋白病变中的焦虑:神经元电路,潜在的病理机制和当前的治疗策略
Thuy Thi Lai1,2, Birthe Gericke1,2, Malte Feja1,2
1Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine, Hannover, Germany.
NPJ Parkinson's disease
|June 22, 2023
概括
像帕金森病这样的同核蛋白病变中的焦虑与大脑恐惧回路中的α-synuclein病理有关. 这表明焦虑可能会推动疾病的进展,而不仅仅是症状.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 神经退行性疾病 神经退行性疾病
背景情况:
- 包括帕金森病 (PD) 在内的同核蛋白病变,以α-synuclein (αSyn) 聚合为特征.
- 焦虑是PD中普遍存在的非运动性症状,显著影响患者的生活质量.
- 杏仁体中的神经病理学,这是一个关键的恐惧和焦虑的大脑区域,与PD相关的焦虑有关.
研究的目的:
- 审查关于同核蛋白病变中神经精神病症状的研究.
- 探索焦虑和恐惧电路在同核蛋白病变中的作用.
- 提供对这些疾病中焦虑的潜在治疗干预措施的见解.
主要方法:
- 对研究的文献综述,研究了同核蛋白病变中的神经精神病症状.
- 对焦虑和恐惧的动物模型中的α-synuclein病理学的研究分析.
- 检查对治疗策略的影响.
主要成果:
- 在动物模型中,在杏仁核中观察到α-synuclein病理,与改变的焦虑反应相关.
- 同核蛋白病变中的焦虑反映了皮层-边缘系统中早期的病原机制.
- 焦虑可能会成为同核蛋白病变中疾病进展的驱动因素.
结论:
- 焦虑是同核蛋白病变发病的组成部分,而不仅仅是次要症状.
- 针对焦虑和恐惧电路,为同核蛋白病变提供了一个新的治疗途径.
- 了解这些电路中的αSyn病理对于开发治疗神经精神症状的有效方法至关重要.
相关概念视频
Parkinson's Disease: Overview
607
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
607
Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
763
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
763
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Chemical Synapses
2.6K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
2.6K
Alzheimer's Disease: Overview
530
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
530


